Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Cetuximab; Docetaxel; Methotrexate
  • Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 141
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 06 Nov 2019 Results for Extrapolating Survival- a Pan-Tumor Perspective on Nivolumab and Ipilimumab presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 06 Nov 2019 Results presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 27 Jun 2019 Results of post hoc subgroup analysis (n=240) published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top